Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia with negative symptoms
Eligibility Criteria
Inclusion: Adults aged 18-60 Current diagnosis of schizophrenia Significant negative symptoms with few positive symptoms (e.g. hallucinations, delusions) and no evidence of major depression. Female subjects of childbearing potential must test negative for pregnancy at the time of enrollment. Subjects must be able to provide consent Must be healthy based on medical exam, laboratory tests and electrocardiogram Exclusion: Female subjects who are either pregnant or nursing. Acute or unstable medical conditions Diseases of the central nervous system Subjects who are judged clinically to be at serious risk for suicide or violence Subjects with delusional disorder, psychotic disorder NOS, schizophreniform, schizoaffective disorder, bipolar disorder, attention deficit/hyperactivity disorder, major depressive disorder,alcohol or drug dependence
Sites / Locations
- Birmingham Psychiatry Pharmaceutical Studies, Inc.
- IPR
- Synergy Clinical Research
- Optimum Health Services
- Sierra Vista Hospital
- Clinical Innovations
- Research Strategies
- University of Colorado
- Psychiatric Institute of Washington
- Berma Research Group
- Segal Institute for Clinical Research
- Quantum Laboratories
- Med Psych Specialists, LLC
- Alexian Brothers Behavioral Health Hospital
- Midwest Center for Neurobehavioral Medicine
- University of Mississippi Medical Center-Dept. of Psychiatry
- CNS Research Institute
- Neurobehavioral Research
- Global Research & Consulting
- Bayley Seton Campus-Psychiatric Research Division
- Behavioral Medical Research of Staten Island, P.C.
- NorthCoast Clinical Trials
- IPS Research
- Vanderbilt University Medical Center
- Community Clinical Research
- MedLabs Research of Houston
- University Hills Clinical Research
- Milwaukee VA Medical Center